Focused on bringing the life-changing power of genetic medicine – to reverse or prevent blindness
ATSENA THERAPEUTICS is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases.
Our lead program is evaluating ATSN-201 in an ongoing Phase I/II clinical trial for X-linked retinoschisis (XLRS), a progressive genetic condition affecting boys and men that is typically diagnosed in childhood. Our other ongoing Phase I/II clinical trial is evaluating ATSN-101 for Leber congenital amaurosis type 1 (LCA1), one of the most common causes of blindness in children.
Our pipeline is powered by novel adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal diseases. Founded by pioneers in ocular gene therapy, we are led by an experienced team dedicated to addressing the needs of patients with vision loss.
Mission
Our mission is to improve the quality of life of patients with inherited retinal disease through the discovery and development of gene therapies that prevent or reverse blindness.
Vision
We strive to create technologies that enable targeted solutions for ocular diseases.
Core Values
Patients & Families: We are dedicated to improving the quality of life of patients with vision loss.
People: We are committed to employing an inclusive, diverse, talented workforce, regardless of location, and treating all people with respect and compassion. We actively optimize virtual collaboration and communication practices and strive for an efficient physical footprint, which allows for an effective balance of in-person and virtual teamwork.
Science: We pride ourselves on being at the cutting edge of ocular gene therapeutics and on bringing them to the clinic with excellence, integrity, and urgency.
Quality & Stewardship: We are committed to responsible stewardship of the resources entrusted to us, as well as 100% compliance to ICH principles and transparency and accountability in all aspects of our business.
